Loading...
Loading...
Browse all stories on DeepNewz
VisitLargest US market share for ATTR-CM treatments by Dec 31, 2025?
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Market research reports and company financial statements
FDA Approves BridgeBio's Attruby (Acoramidis), First Near-Complete TTR Stabilizer for ATTR-CM
Nov 23, 2024, 12:14 AM
BridgeBio Pharma (ticker symbol $BBIO) announced that the U.S. Food and Drug Administration (FDA) has approved Attruby™ (acoramidis), an orally administered near-complete transthyretin (TTR) stabilizer for the treatment of adult patients with transthyretin cardiac amyloidosis (ATTR-CM). Attruby, the first and only approved product specifying near-complete stabilization of TTR (≥90%), was designed to mimic a naturally occurring 'rescue mutation' of the TTR gene (T119M), targeting the root cause of ATTR-CM by preventing destabilization of the native TTR tetramer. The drug is approved to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients. The approval sets up competition with Pfizer, which also markets a treatment for ATTR-CM. Attruby will be priced at approximately $245,000 per year.
View original story
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Pfizer • 25%
Ionis Pharmaceuticals • 25%
Eidos Therapeutics • 25%
Other • 25%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Travere Therapeutics • 25%
Novartis • 25%
Calliditas • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Ascendis Pharma • 25%
Takeda • 25%
Another existing company • 25%
A new entrant • 25%
Aucatzyl (Autolus Therapeutics) • 25%
Kymriah (Novartis) • 25%
Yescarta (Gilead) • 25%
Other • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
$200,000 - $250,000 • 25%
$250,001 - $300,000 • 25%
Below $200,000 • 25%
Above $300,000 • 25%